Table 2 Type-specific prevalence of oncogenic HPV infection in all women with an index high grade cytology

HPV16 (any)

119

49

(43–56)

208

43

(38–47)

327

45

(41–48)

HPV52 (any)

29

12

(8–17)

84

17

(14–21)

113

15

(13–18)

HPV31 (any)

33

14

(10–19)

75

15

(12–19)

108

15

(12–18)

HPV33 (any)

20

8

(5–13)

58

12

(9–15)

78

11

(9–13)

HPV18 (any)

31

13

(9–18)

54

11

(8–14)

85

12

(9–14)

HPV58 (any)

22

9

(6–13)

53

11

(8–14)

75

10

(8–13)

HPV51 (any)

21

9

(6–13)

43

9

(6–12)

64

9

(7–11)

HPV39 (any)

16

7

(4–11)

33

7

(5–9)

49

7

(5–9)

HPV45 (any)

9

4

(2–7)

24

5

(3–7)

33

5

(3–6)

HPV59 (any)

12

5

(3–9)

23

5

(3–7)

35

5

(3–7)

HPV35 (any)

9

4

(2–7)

18

4

(2–6)

27

4

(3–5)

HPV56 (any)

12

5

(3–9)

12

3

(1–4)

24

3

(2–5)

HPV68 (any)

1

0

(0–2)

15

3

(2–5)

16

2

(1–4)

HPV16 and/or 18 (any)

141

59

(52–65)

252

52

(47–56)

393

54

(50–57)

 HPV16 with HPV18 (any)

9

4

(2–7)

9

2

(1–4)

18

3

(2–4)

 HPV16 without HPV18 (any)

110

46

(39–52)

199

41

(36–45)

309

42

(39–46)

 HPV18 without HPV16 (any)

22

9

(6–13)

44

9

(7–12)

66

9

(7–11)

HPV16 and/or 18 (without OHR)

88

37

(30–43)

115

24

(20–28)

203

28

(25–31)

HPV16 and/or 18 (with OHR)

53

22

(17–28)

137

28

(24–32)

190

26

(23–29)

OHR without HPV 16/18

82

34

(28–40)

171

35

(31–39)

253

35

(31–38)

HR HPV (single infection)

137

57

(50–63)

212

43

(39–48)

349

48

(44–52)

HR HPV (any)

222

92

(88–95)

423

87

(83–89)

645

88

(86–91)

HPV positive (including LR HPV)

229

95

(91–97)

450

92

(89–94)

679

93

(91–95)